146858-74-4

Upstream product

• 20925-64-8 7,8-dimethoxy-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 4721-98-6 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline 
• 82044-08-4 N-(tert-butoxycarbonyl)-6,7-dimethoxy-1-methylene-1,2,3,4-tetrahydroisoquinoline 

Downstream Products

• 20925-64-8 7,8-dimethoxy-2-oxo-2,3,4,5-tetrahydro-1H-3-benzazepine 

Relevant academic research and scientific papers

Design of oxa-spirocyclic PHOX ligands for the asymmetric synthesis of lorcaserin: Via iridium-catalyzed asymmetric hydrogenation

Phosphine-oxazoline (PHOX) ligands are a very important class of privileged ligands in asymmetric catalysis. A series of highly rigid oxa-spiro phosphine-oxazoline (O-SIPHOX) ligands based on O-SPINOL was synthesized efficiently, and their iridium complexes were synthesized by coordination of the O-SIPHOX ligands to [Ir(cod)Cl]2 in the presence of sodium tetrakis-3,5-bis(trifluoromethyl)phenylborate (NaBArF). The cationic iridium complexes showed high reactivity and excellent enantioselectivity in the asymmetric hydrogenation of 1-methylene-tetrahydro-benzo[d]azepin-2-ones (up to 99% yield and up to 99% ee). A key intermediate of the anti-obesity drug lorcaserin could be efficiently synthesized using this protocol.